- Press releases - 19.02.2021
Improving immunotherapies for blood cancers: real-time exploration in the tumor
Monoclonal antibodies are part of the therapeutic arsenal for eliminating cancer cells. Some make use of the immune system to act and belong to a class of treatment called “immunotherapies.” But how do these antibodies function within the tumor? And how can we hope to improve their efficacy?
- Press releases - 18.02.2021
Communiquer pendant nos rêves, c’est possible !
Lorsque nous rêvons, nous sommes à première vue coupés du monde, incapables de recevoir des informations de l’environnement et d’y répondre. Pour la première fois, une collaboration entre des chercheurs de l’Inserm, de l’AP-HP, de Sorbonne Université et du CNRS avec plusieurs groupes américains, allemands et néerlandais, montre qu’une communication à double-sens, de l’expérimentateur vers le rêveur et vice-versa est possible au cours du rêve.
- Press releases - 10.02.2021
Was SARS-CoV-2 Already in France in November 2019?
Based on a retrospective analysis of serum samples from over 9,000 adults participating in the French cohort Constances, a study by Inserm researchers found that out of the 353 participants with positive SARS-CoV-2 antibody tests, 13 had had their samples taken between November 2019 and January 2020 – with confirmation by neutralizing antibodies testing. Investigations in 11 of these participants revealed the existence of symptoms possibly related to a SARS-CoV-2 infection or situations at risk of potential SARS-CoV-2 exposure.
- Press releases - 05.02.2021
Maturation et persistance de la réponse lymphocytaire B mémoire anti-SARS-CoV-2
Une étude sur la mémoire immunitaire montre la maturation et la persistance de la mémoire immunitaire B contre le virus SARS-CoV-2 au cours du temps.
- Press releases - 04.02.2021
Focusing on Viral Load to Understand Progression to Severe COVID-19
What are the factors predicting progression to severe forms of COVID-19? One year into the pandemic, this question remains a key research subject, and one that scientists from Inserm and Université de Paris decided to explore further by studying the link between viral kinetics and disease progression.
- Press releases - 01.02.2021
COVID-19 Vaccine Trials: Janssen’s Vaccine Candidate to be Tested by Covireivac
The Phase 3 clinical trial of a COVID-19 vaccine is to be launched via Covireivac, a platform set up under the auspices of Inserm and the university hospitals to centralize COVID-19 vaccine trials in France. Janssen, the pharmaceutical division of the Johnson & Johnson group, has obtained the authorizations needed for ENSEMBLE 2, a trial evaluating the efficacy and safety of vaccine candidate Ad26.COV2.S in the prevention of COVID-19 in adults. In France, 1175 volunteers out of those registered on Covireivac will enroll in this clinical trial that will be conducted in 30,000 people across the world.
- Press releases - 29.01.2021
Better Access to Education Reduces Differences in Cognitive Capacity Between Men and Women
Elderly women are currently at a higher risk than men of developing dementia, particularly Alzheimer’s disease. A phenomenon that could partially be explained by inequalities in access to education between the sexes during the first half of the 20th century. Researchers from Inserm and Université de Paris, in collaboration with University College London, have shown that certain cognitive capacities have improved in women over recent generations, and that this is linked to a larger number of women accessing higher education.
- Press releases - 28.01.2021
Covid-19: Understanding Early Immune Response
As the COVID-19 pandemic continues, scientists are making significant headway in understanding the transmission of the SARS-CoV-2 coronavirus and the immune response it triggers at the time of infection. Researchers have provided new data on the very early stages of immune response.
- Press releases - 27.01.2021
Discovery stops testing Remdesivir against Covid-19 for lack of evidence of its efficacy
The Discovery trial was originally launched in March 2020 by Inserm to evaluate possible treatments for Covid-19. On January 13th, 2021, the Discovery Europe trial Data Safety Monitoring Boards (DSMB) evaluated an interim report based on 776 patients of whom 389 received remdesivir and 387 received standard of care. The efficacy of the treatment was evaluated after 15 days and measured on the WHO-7-point ordinal scale. As a result of the evaluation, the DSMB recommended that patient recruitment be suspended.
- Press releases - 25.01.2021
À l’Inserm, la lutte contre la pandémie de Covid-19 se poursuit
Pour faire face à la pandémie de Covid-19, mieux comprendre le virus et accompagner la prise en charge des maladies, les scientifiques de l’Inserm sont plus que jamais mobilisés.